SAN DIEGO, July 15, 2026, 13:07 (PDT)
- Lilly’s payment is 38.2 times VivoSim’s 2026 fiscal revenue, and about 1.7 times the company’s closing equity value. B:
- The payment from Lilly comes out to 38.2 times VivoSim’s fiscal 2026 revenue, or about 1.7 times its closing equity value.
- If revenue rises 500%, it would reach $786,000. That’s roughly 7.3% of the planned operating expense for fiscal 2027.
VivoSim Labs, Inc. NASDAQ:VIVS reported Wednesday it got a $5 million milestone payment from Eli Lilly and Company NYSE:LLY, bringing in cash worth about 1.7 times VivoSim’s equity value at Tuesday’s close and recent share count. Still, shares ended up just 3.0% at $0.8599, slipping from an open of $1.49.
Lilly paid the fee after dosing the first patient in its Phase 2 trial of FXR314, the inflammatory bowel drug it picked up from VivoSim in March 2025. Lilly is running the program, but VivoSim can get up to $45 million more if it hits certain regulatory and sales milestones.
The key issue for investors is what backs VivoSim’s forecast for over 500% revenue growth in fiscal 2027. The company brought in just $131,000 in revenue for fiscal 2026, all from royalties. If it grows 500% from that level, revenue would hit $786,000. The release on Wednesday didn’t break out any more detailed dollar targets.
Based on VivoSim’s annual filing, the spending plan and cash-flow numbers suggest the milestone is really just funding to keep operations going, not evidence of big operating scale.
| Financial measure | Reported or implied amount | Investor comparison |
|---|---|---|
| Fiscal-2026 revenue | $0.131 million | Used as the growth base |
| Revenue at 500% growth threshold | $0.786 million | Equals 7.3% of planned fiscal-2027 operating costs |
| Lilly milestone | $5.0 million | That’s 38.2 times 2026 revenue; just under half of planned expense |
| Fiscal-2026 cash used in operations | $10.827 million | This payment covers about 5.5 months of prior-year spend rate |
If revenue hits 500% growth, the gap with the $10.7 million in operating expenses management targets this fiscal year stays close to $9.9 million. Faster top-line growth would cut that difference. The one-time payment covers almost half of the year’s spending but doesn’t make the contract research unit self-sustaining.
Wednesday saw traders split again on the value of the cash payout versus faith in the core business.
| Trading measure | Wednesday figure | Comparison |
|---|---|---|
| Closing price | $0.8599, up 3.0% | Still down 42.3% from the $1.49 open |
| Volume | 112.4 million shares | That’s 32.2 times the shares traded on July 10 |
| Implied closing equity value | About $3.0 million | Lilly’s payment is 1.66 times that amount |
Trading volume topped 112 million shares, compared with just 3.49 million shares outstanding. That doesn’t mean the stock turned over 32 times, since shares can be bought and sold more than once, but trading spiked after the news. The stock closed near its session low, which mattered more than the early jump.
VivoSim is looking to sell contract research using its 3D human liver and intestine models. New approach methodologies, or NAMs, use non-animal, human-based lab and computer methods before clinical trials. The U.S. Food and Drug Administration has said these methods could make drug testing better, and has listed places where sponsors can pitch them, but actual acceptance depends on the context.
The company reported its liver model reached 91% predictive accuracy, while its intestine model delivered over 90% sensitivity and accuracy. These numbers come from the company. But for the stock, what will matter is paid contract work and customer renewals—VivoSim did not give those numbers in its release Wednesday.
The annual report flagged “substantial doubt about our ability to continue as a going concern” due to tight liquidity, and management says they’ll need a lot more cash. It counted 3.95 million 2026 common warrants, which let holders buy at a fixed price, still outstanding as of March 31, against 3.49 million common shares on July 10. The $1.71 exercise price is higher than where shares closed Wednesday. The last $45 million from Lilly isn’t in hand—it’s contingent. SEC
Investors are likely to watch contract-research revenue as the real signal, not the asset-sale milestone. The $5 million payment gives VivoSim more runway to market its models. The 500%-plus revenue forecast still starts at $131,000. Next filing will show if that growth target turns into real revenue.
